Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Praxair Inc. ( PX - Analyst Report ) together with its divisions and subsidiaries has announced escalation in gas prices in order to cover the increasing expenses of manufacturing, distribution, and raw material sourcing costs as well as for financing further investment activities.
Prices of nitrogen and oxygen have been increased up to 12% while argon and hydrogen prices have been raised to 18%. Facility fees or monthly bulk product charges and cylinder rental rates have gone up by 15% while prices for hardwoods have increased upto 15%.
The price rise, effective from June 1, 2012, will be applicable to the bulk and packaged industrial, electronics, specialty and medical gas customers in the United States, Canada and Puerto Rico.
Of late, the company posted upbeat first quarter 2012 results with earnings per share of $1.38 surpassing the Zacks Consensus Estimate by 2 cents. Revenue moved up 5% attributable to healthy performance in North America and Asia.
Air Products & Chemicals Inc. ( APD - Analyst Report ) , Praxair’s prime competitor, reported earnings of $1.31 per share versus $1.33 reported in the year-ago quarter. Results were below the Zacks Consensus Estimate of $1.33 per share.
Long-term prospect looks promising for Praxair with increasing application areas for industrial gases. Chemical processing, petroleum refining, metal production, fabricating, electronics and health care industries are widely using these gases. By 2015, the company targets to achieve annual organic sales growth of 8%-12%; operating profit growth of 10%-15%, and earnings growth of 12%-18%.
The current Zacks Consensus Estimate for the second quarter stands at $1.45, representing a year-over-year increase of 4.74%. Estimates for the fiscal years 2012 and 2013 are $5.85 and $6.66, reflecting annual growth of 7.76% and 13.89%, respectively.
We currently maintain a Neutral recommendation on Praxair.
Read the full reports :
Analyst Report on PX
Analyst Report on APD